Q2 FY2026 Earnings
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Chemomab Therapeutics(CMMB) the EBIT is -2.241 M (+0.93%), Beat estimate;the EPS is -0.003 (+81.25%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.00B0.93%
-0.00B7.67%
+0.00B8.60%
EPSMiss expectations
-0.00381.25%
0100.00%
-0.003018.75%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf